New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma
Pharmacy Times
JUNE 27, 2025
Mary Dzhuryan is a class of 2026 PharmD candidate at the USC Alfred E. Mehrnaz Razavi Vakhshoori is a class of 2026 PharmD candidate at the USC Alfred E. Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. Mann School of Pharmacy and Pharmaceutical Sciences in Los Angeles.
Let's personalize your content